vanessa, if that is what you want to know from PPHM management via a lawsuit then maybe you should have reacted when they STARTED going it alone, and not now that, after a result of a double blinded trial on which they had no field execution involvement, they must change course because their I-O drug bavituxumab has more future in Immuno-Therapy then in chemo if you would need to start Docetaxel+Bavi all over.
I was 100% behind going it alone in the Chemo/Radio + Bavituximab arena, and if SUNRISE would not have had an abnormally outperforming control arm then they would have made it, possibly with a BIG or BIGGER handicap to get into the Immuno-Therapy because all BPs would have seen them as hostile and disruptive to their multi-billion I-O programs they have running and would then suddenly have to beat a much higher SOC.
Today I agree, with hindsight because we know what the market did since Q3/2012 and how it mainly changed with the ASCO 2013 announcement about I-O (Opdivo/KeyTruda), that going it alone is NO LONGER an option. And as geocappy said, we do not just need something that is called a "partnership" we need one that brings cash to the table and allows to advance the bavituximab program at HIGH SPEED.
Personally I think that is what is about to happen. But from their starting a lawsuit against management for not explaining why they attempted to go it alone...no, thanks.
News 
Market Data 
Discover 
AI
